BIOMAT Database Logo BIOMAT Database Logo

Immune response to inactivated syngeneic mammary adenocarcinoma cells. I. Role and regulation of antibody synthesis in DBA/2 mice. 1980

F DeLustro, and J S Haskill

The immunogenicities of irradiated T1699 murine mammary adenocarcinoma cells (XR-T1699) and mitomycin C-treated T1699 cells (T1699m) were compared with respect to eliciting humoral immunity, cell-mediated immunity, and protection against subsequent sc challenge with untreated T1699 tumor cells (T1699u) in the syngeneic host (DBA/2 mice). Treatment with 10(3)-10(7) T1699m failed to induce any immunity against subsequent challenge with viable T1699u, whereas 10(6)-10(7) XR-T1699 sensitized the host to later challenge with T1699u. Although both T1699m- and XR-T1699-sensitized mice displayed a delayed hypersensitivity response to soluble T1699 antigen as determined by footpad swelling, only XR-T1699-immunized mice developed detectable levels of anti-T1699 antibody, as measured by indirect immunofluorescence. The antibody-dependent cellular cytotoxicity (ADCC) titer of sera from XR-T1699-immunized mice peaked at day 11 and declined by day 20, whereas sera from T1699m- sensitized mice showed no detectable ADCC activity. Sera from mice with progressing T1699u tumors showed high levels of ADCC activity at all times tested. The immunity induced by XR-T1699 injection was shown to be specific for T1699 tumor cells and not limited to the anatomic area of immunization. The results are discussed in terms of the role of antibody as the primary protective mechanism in sensitization in the T1699 tumor model.

UI MeSH Term Description Entries
D006968 Hypersensitivity, Delayed An increased reactivity to specific antigens mediated not by antibodies but by sensitized T CELLS. Hypersensitivity, Tuberculin-Type,Hypersensitivity, Type IV,Tuberculin-Type Hypersensitivity,Type IV Hypersensitivity,Delayed Hypersensitivity,Delayed Hypersensitivities,Hypersensitivity, Tuberculin Type,Tuberculin Type Hypersensitivity,Tuberculin-Type Hypersensitivities,Type IV Hypersensitivities
D007109 Immunity Nonsusceptibility to the invasive or pathogenic effects of foreign microorganisms or to the toxic effect of antigenic substances. Immune Process,Immune Response,Immune Processes,Immune Responses,Process, Immune,Response, Immune
D008325 Mammary Neoplasms, Experimental Experimentally induced mammary neoplasms in animals to provide a model for studying human BREAST NEOPLASMS. Experimental Mammary Neoplasms,Neoplasms, Experimental Mammary,Experimental Mammary Neoplasm,Mammary Neoplasm, Experimental,Neoplasm, Experimental Mammary
D008811 Mice, Inbred DBA An inbred strain of mouse. Specific substrains are used in a variety of areas of BIOMEDICAL RESEARCH such as DBA/1J, which is used as a model for RHEUMATOID ARTHRITIS. Mice, DBA,Mouse, DBA,Mouse, Inbred DBA,DBA Mice,DBA Mice, Inbred,DBA Mouse,DBA Mouse, Inbred,Inbred DBA Mice,Inbred DBA Mouse
D008937 Mitomycins A group of methylazirinopyrroloindolediones obtained from certain Streptomyces strains. They are very toxic antibiotics used as ANTINEOPLASTIC AGENTS in some solid tumors. PORFIROMYCIN and MITOMYCIN are the most useful members of the group.
D005260 Female Females
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000912 Antibodies, Neoplasm Immunoglobulins induced by antigens specific for tumors other than the normally occurring HISTOCOMPATIBILITY ANTIGENS. Neoplasm Antibodies,Tumor Antibodies,Antibodies, Tumor
D000920 Antibody-Dependent Cell Cytotoxicity The phenomenon of antibody-mediated target cell destruction by non-sensitized effector cells. The identity of the target cell varies, but it must possess surface IMMUNOGLOBULIN G whose Fc portion is intact. The effector cell is a "killer" cell possessing Fc receptors. It may be a lymphocyte lacking conventional B- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent. ADCC,Cytotoxicity, Antibody-Dependent Cell,Cell Cytoxicity, Antibody-Dependent,Antibody Dependent Cell Cytotoxicity,Antibody-Dependent Cell Cytotoxicities,Antibody-Dependent Cell Cytoxicities,Antibody-Dependent Cell Cytoxicity,Cell Cytotoxicities, Antibody-Dependent,Cell Cytotoxicity, Antibody-Dependent,Cell Cytoxicities, Antibody-Dependent,Cell Cytoxicity, Antibody Dependent,Cytotoxicities, Antibody-Dependent Cell,Cytotoxicity, Antibody Dependent Cell,Cytoxicities, Antibody-Dependent Cell,Cytoxicity, Antibody-Dependent Cell

Related Publications

F DeLustro, and J S Haskill
Immune response to a syngeneic mammary adenocarcinoma. I. Comparison of kinetics of tumor cell growth and cytotoxic responses in syngeneic and allogeneic rats.
November 1975, Journal of immunology (Baltimore, Md. : 1950),
F DeLustro, and J S Haskill
Antibody response to embryonal carcinoma cells in syngeneic mice.
December 1979, European journal of immunology,
F DeLustro, and J S Haskill
Immune response to a syngeneic mammary adenocarcinoma. II. In vitro generation of cytotoxic lymphocytes.
November 1975, Journal of immunology (Baltimore, Md. : 1950),
F DeLustro, and J S Haskill
Immune response against P815X2 mastocytoma growing in syngeneic DBA/2 mice. I. Morphometric assessment of lymph node immunoreactivity and analysis of circulating antibodies.
January 1986, Experimental pathology,
F DeLustro, and J S Haskill
Immune response against P815X2 mastocytoma growing in syngeneic DBA/2 mice. V. Spleen immunoreactivity and cell mediated cytotoxicity.
January 1987, Archiv fur Geschwulstforschung,
F DeLustro, and J S Haskill
Cycling of immune responses to a syngeneic murine mammary adenocarcinoma.
October 1980, Cancer research,
F DeLustro, and J S Haskill
A bispecific antibody prolongs survival in mice bearing lung metastases of syngeneic mammary adenocarcinoma.
June 1995, International immunology,
F DeLustro, and J S Haskill
Immune response against P815X2 mastocytoma growing in syngeneic DBA/2 mice. IV. Lymph node immunoreactivity and cell-mediated cytotoxicity.
January 1987, Neoplasma,
F DeLustro, and J S Haskill
Antibody response to lymphoma antigens in syngeneic and H-2 compatible mice.
November 1976, Journal of immunology (Baltimore, Md. : 1950),
F DeLustro, and J S Haskill
Suppressor lymphokine produced by rat T-cells in response to syngeneic mammary adenocarcinoma 13762A.
February 1988, Cancer research,
Copied contents to your clipboard!